Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
Journal of Clinical Medicine · 30.07.2023 · 12 (15) · 5014
DOI: 10.3390/jcm12155014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.07.2023. Verfasst von Sarah Bencardino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, 20132 Milan, Italy. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that negatively impacts patients’ quality of life. In the last decades, the therapeutic options available for the management of patients with moderate to severe UC have increased significantly, including not only biological drugs but also small molecules. However, there is a persistent need to develop new drugs that act on new targets while minimizing the risk of adverse events. Sphingosine-1-phosphate (S1P) is a membrane-derived lysophospholipid. The S1P gradient between tissues and the circulatory system has a key role in regulating the trafficking of immune cells as autoreactive B and T lymphocytes. S1P receptor modulators could be a safe and efficacious alternative mechanism for reducing inflammation in immune-mediated disorders, including UC, by reducing lymphocyte egress from the lymph nodes to the bloodstream. Several S1P receptor modulators have been developed and tested in UC. Ozanimod is already approved by Food and Drug Administration (FDA) and European Medical Agency (EMA), while etrasimod and VTX002 are still under approval. Oral administration route, rapidity and reliable safety profile are the main advantages of this class of drugs. The aim of this review is to summarize the available evidence for the efficacy, safety, and pharmacokinetics of ozanimod, etrasimod, and VTX002 in UC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, 20132 Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20072 Milan, Italy.
- Department of Gastroenterology, University of Lorraine, CHRU-Nancy, F-54000 Nancy, France.
- Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
- INSERM, NGERE, University of Lorraine, F-54000 Nancy, France.
- INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
ORCID-Profile: Sarah Bencardino, Gionata Fiorino, Silvio Danese
Zitieren
APA
Bencardino, S., D'Amico, F., Faggiani, I., Bernardi, F., Allocca, M., Furfaro, F., Parigi, T. L., Zilli, A., Fiorino, G., Peyrin-Biroulet, L., & Danese, S. (2023). Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. Journal of Clinical Medicine, 12(15), 5014. https://doi.org/10.3390/jcm12155014
Vancouver
Bencardino S, D'Amico F, Faggiani I, Bernardi F, Allocca M, Furfaro F, et al. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. Journal of Clinical Medicine. 2023;12(15):5014. doi:10.3390/jcm12155014
BibTeX
@article{Bencardino2023,
author = {Bencardino, Sarah and D'Amico, Ferdinando and Faggiani, Ilaria and Bernardi, Francesca and Allocca, Mariangela and Furfaro, Federica and Parigi, Tommaso Lorenzo and Zilli, Alessandra and Fiorino, Gionata and Peyrin-Biroulet, Laurent and Danese, Silvio},
title = {Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {15},
pages = {5014},
doi = {10.3390/jcm12155014}
}
EUVIMED